Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Cotellic (cobimetinib)
i
Other names:
GDC-0973, RG-7420, XL518, RO 5514041, RG7421, XL-518, R-7421, RO-5514041, GDC 0973, R 7421, GDC0973, R7421, RG 7421, RO5514041, XL 518
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(94)
News
Trials
Company:
Exelixis, Roche
Drug class:
MEK1 inhibitor
Related drugs:
‹
U0126 (10)
REC-4881 (6)
IMM-1-104 (5)
FCN-159 (4)
SHR7390 (3)
E6201 (1)
ABM-168 (0)
BI 847325 (0)
PD198306 (0)
TQ-B3234 (0)
U0126 (10)
REC-4881 (6)
IMM-1-104 (5)
FCN-159 (4)
SHR7390 (3)
E6201 (1)
ABM-168 (0)
BI 847325 (0)
PD198306 (0)
TQ-B3234 (0)
›
Associations
(94)
News
Trials
VERI cancer hierarchy
Reset Filters
BRAF V600
Melanoma
BRAF V600
Melanoma
atezolizumab + vemurafenib + cobimetinib
Sensitive: A1 - Approval
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A1
atezolizumab + vemurafenib + cobimetinib
Sensitive: A1 - Approval
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600K
Melanoma
BRAF V600K
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600E
Ganglioglioma
BRAF V600E
Ganglioglioma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
vemurafenib + cobimetinib
Sensitive
:
A2
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
vemurafenib + cobimetinib
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
BRAF V600
Cutaneous Melanoma
atezolizumab + vemurafenib + cobimetinib
Sensitive: A2 - Guideline
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A2
atezolizumab + vemurafenib + cobimetinib
Sensitive: A2 - Guideline
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
BRAF V600
Cutaneous Melanoma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
vemurafenib + cobimetinib
Sensitive
:
A2
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
vemurafenib + cobimetinib
Sensitive
:
A2
BRAF V600E
Astrocytoma
BRAF V600E
Astrocytoma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
vemurafenib + cobimetinib
Sensitive
:
A2
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
vemurafenib + cobimetinib
Sensitive
:
A2
BRAF V600E
Astrocytoma
BRAF V600E
Astrocytoma
cobimetinib
Sensitive: A2 - Guideline
cobimetinib
Sensitive
:
A2
cobimetinib
Sensitive: A2 - Guideline
cobimetinib
Sensitive
:
A2
BRAF V600E
Ganglioglioma
BRAF V600E
Ganglioglioma
cobimetinib
Sensitive: A2 - Guideline
cobimetinib
Sensitive
:
A2
cobimetinib
Sensitive: A2 - Guideline
cobimetinib
Sensitive
:
A2
BRAF V600E
Cutaneous Melanoma
BRAF V600E
Cutaneous Melanoma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
vemurafenib + cobimetinib
Sensitive
:
A2
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
vemurafenib + cobimetinib
Sensitive
:
A2
No biomarker
Colorectal Cancer
No biomarker
Colorectal Cancer
atezolizumab + cobimetinib
Resistant: A2 - Guideline
atezolizumab + cobimetinib
Resistant
:
A2
atezolizumab + cobimetinib
Resistant: A2 - Guideline
atezolizumab + cobimetinib
Resistant
:
A2
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.